Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia.

IF 3.1 3区医学 Q2 HEMATOLOGY Current Opinion in Hematology Pub Date : 2023-03-01 Epub Date: 2022-12-23 DOI:10.1097/MOH.0000000000000749

Andrew M Brunner

{"title":"Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia.","authors":"Andrew M Brunner","doi":"10.1097/MOH.0000000000000749","DOIUrl":null,"url":null,"abstract":"Purpose of review: Therapies that target the immune system are increasingly used across oncology, including in hematologic malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). While allogeneic transplant has been a key therapy in these cancers, new approaches that target the immune system are being explored including immune checkpoint therapies, antibody-drug conjugates, and cellular therapies.Recent findings: This review outlines updates in the preclinical rationale for immune directed therapies in MDS and AML, as well as recent clinical trials exploring these therapies. This manuscript summarizes the development of therapies targeting T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) and CD47, which are being evaluated in late phase studies in MDS and AML. It also reviews the landscape of other immune based therapies including antibody-drug conjugates, chimeric antigen receptor-T cells, bispecific antibodies, and tumor vaccines.Summary: The treatment landscape in MDS and AML is rapidly changing; with a goal of improving the quality and duration of responses, a number of immune based therapies are under investigation. This review outlines recent advances with these therapies as well as some of the challenges that remain to incorporate them into leukemia care.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017015/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOH.0000000000000749","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/12/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Therapies that target the immune system are increasingly used across oncology, including in hematologic malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). While allogeneic transplant has been a key therapy in these cancers, new approaches that target the immune system are being explored including immune checkpoint therapies, antibody-drug conjugates, and cellular therapies.

Recent findings: This review outlines updates in the preclinical rationale for immune directed therapies in MDS and AML, as well as recent clinical trials exploring these therapies. This manuscript summarizes the development of therapies targeting T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) and CD47, which are being evaluated in late phase studies in MDS and AML. It also reviews the landscape of other immune based therapies including antibody-drug conjugates, chimeric antigen receptor-T cells, bispecific antibodies, and tumor vaccines.

Summary: The treatment landscape in MDS and AML is rapidly changing; with a goal of improving the quality and duration of responses, a number of immune based therapies are under investigation. This review outlines recent advances with these therapies as well as some of the challenges that remain to incorporate them into leukemia care.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

骨髓增生异常综合征和急性髓性白血病的新型免疫导向疗法。

综述目的：针对免疫系统的疗法越来越多地应用于肿瘤学领域，包括骨髓增生异常综合征（MDS）和急性髓性白血病（AML）等血液系统恶性肿瘤。虽然异基因移植一直是治疗这些癌症的关键疗法，但目前正在探索针对免疫系统的新方法，包括免疫检查点疗法、抗体药物共轭物和细胞疗法：本综述概述了 MDS 和 AML 免疫导向疗法临床前原理的最新进展，以及探索这些疗法的最新临床试验。本手稿总结了以T细胞免疫球蛋白和含粘蛋白结构域的蛋白3（TIM-3）和CD47为靶点的疗法的发展情况，这些疗法正在MDS和AML的晚期研究中进行评估。摘要：MDS 和 AML 的治疗形势正在发生迅速变化；为了提高反应的质量和持续时间，许多免疫疗法正在接受研究。本综述概述了这些疗法的最新进展，以及将这些疗法纳入白血病治疗仍面临的一些挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Opinion in Hematology 医学-血液学

CiteScore

6.60

自引率

3.10%

发文量

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Hematology is an easy-to-digest bimonthly journal covering the most interesting and important advances in the field of hematology. Its hand-picked selection of editors ensure the highest quality selection of unbiased review articles on themes from nine key subject areas, including myeloid biology, Vascular biology, hematopoiesis and erythroid system and its diseases.